RhumbLine Advisers
CTMX icon

RhumbLine Advisers’s CytomX Therapeutics CTMX Stock Holding History

RhumbLine Advisers’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$834K Buy
+222,514
New +$850K ﹤0.01% 2435
2024
Q3 		– Sell
-1,291
Closed -$1.57K – 4228
2024
Q2 		$1.57K Hold
1,291
– – ﹤0.01% 4204
2024
Q1 		$2.81K Hold
1,291
– – ﹤0.01% 4054
2023
Q4 		$2K Hold
1,291
– – ﹤0.01% 4092
2023
Q3 		$1.67K Hold
1,291
– – ﹤0.01% 4128
2023
Q2 		$2.22K Buy
+1,291
New +$2.14K ﹤0.01% 4203
2022
Q2 		– Sell
-67,376
Closed -$180K – 3124
2022
Q1 		$180K Buy
67,376
+428
+0.6% +$1.64K ﹤0.01% 2782
2021
Q4 		$290K Sell
66,948
-985
-1% -$5.77K ﹤0.01% 2716
2021
Q3 		$346K Buy
67,933
+3,757
+6% +$20.1K ﹤0.01% 2706
2021
Q2 		$406K Buy
64,176
+3,190
+5% +$24.8K ﹤0.01% 2656
2021
Q1 		$471K Buy
60,986
+1,845
+3% +$14.6K ﹤0.01% 2521
2020
Q4 		$387K Buy
59,141
+3,310
+6% +$23.6K ﹤0.01% 2550
2020
Q3 		$371K Sell
55,831
-7,790
-12% -$57.8K ﹤0.01% 2427
2020
Q2 		$530K Buy
63,621
+2,956
+5% +$27.5K ﹤0.01% 2315
2020
Q1 		$465K Sell
60,665
-1,690
-3% -$11.8K ﹤0.01% 2193
2019
Q4 		$518K Buy
62,355
+1,147
+2% +$7.74K ﹤0.01% 2341
2019
Q3 		$452K Buy
61,208
+921
+2% +$9.09K ﹤0.01% 2368
2019
Q2 		$676K Buy
60,287
+2,500
+4% +$26.2K ﹤0.01% 2238
2019
Q1 		$621K Sell
57,787
-1,356
-2% -$20K ﹤0.01% 2236
2018
Q4 		$893K Buy
59,143
+21,402
+57% +$318K ﹤0.01% 2064
2018
Q3 		$698K Buy
37,741
+689
+2% +$15.7K ﹤0.01% 2148
2018
Q2 		$847K Buy
37,052
+8,100
+28% +$207K ﹤0.01% 2086
2018
Q1 		$824K Buy
28,952
+200
+0.7% +$5.71K ﹤0.01% 2027
2017
Q4 		$607K Sell
28,752
-4,245
-13% -$88K ﹤0.01% 2159
2017
Q3 		$600K Buy
32,997
+480
+1% +$7.49K ﹤0.01% 2221
2017
Q2 		$504K Buy
32,517
+10,607
+48% +$160K ﹤0.01% 2300
2017
Q1 		$378K Buy
21,910
+872
+4% +$11.5K ﹤0.01% 2384
2016
Q4 		$231K Buy
21,038
+3,812
+22% +$46.2K ﹤0.01% 2615
2016
Q3 		$270K Buy
17,226
+2,300
+15% +$27.8K ﹤0.01% 2534
2016
Q2 		$152K Buy
+14,926
New +$170K ﹤0.01% 2830

Other funds holding CTMX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

RhumbLine Advisers's CTMX Position: Q2 2026 in Review

RhumbLine Advisers opened a new position in CytomX Therapeutics (CTMX) in Q2 2026: 222,514 shares worth $834K. The stake represents ﹤0.01% of the portfolio and ranks #2435 among its holdings. This is a return to the name: RhumbLine Advisers previously reported a position in CTMX as recently as Q2 2024.

RhumbLine Advisers first reported a position in CTMX in Q2 2016 and has held it in 30 quarters since. The position peaked at $893K in Q4 2018. 178 funds tracked by Wall St. Rank hold CTMX as of Q2 2026.

  • RhumbLine Advisers held 222,514 shares of CytomX Therapeutics worth $834K as of Q2 2026.
  • CytomX Therapeutics was a new RhumbLine Advisers position in Q2 2026.
  • CytomX Therapeutics made up ﹤0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #2435 holding.
  • RhumbLine Advisers first reported a position in CytomX Therapeutics in Q2 2016 and has held it in 30 quarters since.
  • RhumbLine Advisers's CytomX Therapeutics position peaked at $893K in Q4 2018.
  • 178 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.